UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
study id #: NCT02254863
condition: Adrenoleukodystrophy, Batten Disease, Mucopolysaccharidosis II, Leukodystrophy, Globoid Cell, Leukodystrophy, Metachromatic, Neimann Pick Disease, Pelizaeus-Merzbacher Disease, Sandhoff Disease, Tay-Sachs Disease, Brain Diseases, Metabolic, Inborn, Alpha-Mannosidosis, Sanfilippo Mucopolysaccharidoses
The primary objective of the study is to determine the safety and feasibility of intrathecal administration of DUOC-01 as an adjunctive therapy in patients with inborn errors of metabolism who have evidence of early demyelinating disease in the central nervous system (CNS) who are undergoing standard treatment with unrelated umbilical cord blood transplantation (UCBT). The secondary objective of the study is to describe the efficacy of UCBT with intrathecal administration of DUOC-01 in these patients.
last updated: February 26, 2022
start date: September 2014
estimated completion: September 2022
last updated: December 14, 2021
phase of development: Phase 1
size / enrollment: 12
study description: The inherited metabolic disorders (IMD) are a heterogeneous group of genetic diseases, most of which involve a single gene mutation resulting in an enzyme defect. In the majority of cases, the enzyme defect leads to the accumulation of substrates that are toxic and/or interfere with normal cellular function. Often times, patients may appear normal at birth but during infancy begin to exhibit disease manifestations, frequently including progressive neurological deterioration due to absent or abnormal brain myelination. The ultimate result is death in later infancy or childhood.
Currently, the only effective therapy to halt the neurologic progression of disease is allogeneic hematopoietic stem cell transplantation (HSCT), which serves as a source of permanent cellular ERT.3 However, one barrier to the success of this therapy is delayed engraftment of donor cells in the CNS when administered through the intravenous route, which is associated with ongoing disease progression over 2-4 months before stabilization. The engraftment of donor cells in a patient with an IMD provides a constant source of enzyme replacement, thereby slowing or halting the progression of disease.
This study will evaluate the safety of a potential new treatment for patients with certain IMDs known to benefit from HSCT using allogeneic UCB donor cells. The new intervention, intrathecal administration of UCB-derived oligodendrocyte-like cells (DUOC-01) will serve as an adjunctive therapy to a standard UCB transplant. The goal of this therapy is to accelerate delivery of donor cells to the CNS thereby bridging the gap between systemic transplant and engraftment of cells in the CNS and preventing disease progression. The DUOC-01 cells and cells used for HSCT will be derived from the same UCB donor unit.
- Evaluate for Infusional Toxicity
Will monitor for fever, vomiting, neck stiffness, seizures, changes in state of consciousness
- 24 hours after infusion
Evaluate for Neuro Toxicity
Perform computerized tomography (CT) scan to evaluate for bleeding, tumor formation, central nervous system generalized infiltration
- 1 month after infusion
- Efficacy determination
• Eligible Sexes: all
Patients must be age ≥1 week to <21 years.
Patients must have one of the following inherited metabolic diseases detected by enzyme or mutation analysis, and confirmed by repeat testing on a separately obtained sample:
Adrenoleukodystrophy (ALD) Batten Disease Hunter Syndrome (MPS II) Krabbe disease (Globoid Leukodystrophy) Metachromatic Leukodystrophy (MLD) Niemann Pick disease type A or B Pelizaeus-Merzbacher disease (PMD) Sandhoff disease Tay Sachs disease. Alpha Mannosidosis Sanfilippo (MPS III)
Patients must have neurologic evidence of their disease, either clinically or via neuroimaging or neurophysiological testing. Examples of evidence of neurologic involvement include, but are not limited to the following:
Abnormal EEG, Brainstem Auditory Evoked Response (BAER), and/or Visual Evoked Potentials (VEP).
Abnormal brain MRI, ie. increased Loes score (measure of white matter damage, demyelination, and brain atrophy) and/or abnormal corticospinal tracts as assessed by MRI with diffusion tensor imaging (DTI).
Three or more of the early clinical markers: problems sleeping, increased activity, behavior difficulties, seizure-like activity, chewing behavior, inappropriate bladder training, inappropriate bowel training.
Patients must have adequate organ function as measured by:
Renal: Serum creatinine < 2.0 mg/dl
Hepatic: Hepatic transaminases (ALT/AST) < 5 x normal, bilirubin < 2.0 mg/dl (except in patients with Gilbert's disease or newborns with physiological or breast milk associated jaundice).
Cardiac: Normal cardiac function by echocardiogram or radionuclide scan (shortening fraction or ejection fraction
80% of normal value for age). Patients with acquired or congenital cardiomyopathy may receive melphalan as a substitute for cyclophosphamide.
Pulmonary: Pulmonary function tests demonstrating FVC, FEV1, and DLCO ≥ 60% of predicted in patients who can complete the testing. If patient cannot perform PFT's, an O2 sat must be >90% on room air.
Patients must not have a suitable fully matched, non-carrier sibling or related bone marrow donor.
Patients must have an available, suitably matched, banked UCB unit in a two-compartment configuration (see graft selection criteria in section 5.2).
Patients must have a performance status as follows: Lansky ≥ 40%, or Karnofsky ≥ 40%.
Patients must have a life expectancy of ≥ 6 months.
exclusion criteria: Criteria:
Prior organ, tissue, or stem cell transplant within 3 years of study entry.
Prior participation in any gene or regenerative cell therapy study.
Inability to have an MRI scan or lumbar puncture.
Evidence of HIV infection or HIV positive serology.
Uncontrolled bacterial, viral, or fungal infection at the time of pre-UCBT cytoreduction.
Inability to obtain patient's, parent's or legal guardian's consent.
Requirement of ventilatory support.
Pregnant or breastfeeding.
Active concurrent malignancy, or receiving concurrent radiotherapy, immunosuppressive medications, or cytotoxic chemotherapy
sponsor: Joanne Kurtzberg, MD
contacts: Sydney Crane, RN, email@example.com
investigators: Joanne Kurtzberg, MD,Duke University
trial center locations: United States
United States, North Carolina
Duke University Medical Center
Sydney Crane, RN, firstname.lastname@example.org
A Rare Specialism: A Look at the Last Ten Years in MPS Management, Presented by Dr Christina Lampehttps://www.youtube.com/watch?v=EjNEVoWT...
Fatal Care Research FoundationFatal Care Research Center inaugurated a...
Identification and Structure Characterization of Novel IDS Variants Causing Mucopolysaccharidosis Type II: A Retrosp...Mucopolysaccharidosis type II (MPS II) o...
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th ...REGENXBIO Inc. (Nasdaq: RGNX) today anno...
Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis Type IMusculoskeletal findings in MPS can prog...
Nationwide Newborn Screening Program for Mucopolysaccharidoses in Taiwan and An Update of the “Gold Standard&#...Mucopolysaccharidoses (MPSs) are a group...
Molecular Analysis of Vietnamese Patients With Mucopolysaccharidosis Type IMucopolysaccharidosis type I (MPS I) is ...